Prophylix Pharma AS is developing a new prophylactic treatment against Neonatal Alloimmune Thrombocytopenia (NAIT), a serious condition which affects the newborn and remains an unmet medical need.
info@prophylixpharma.com
http://prophylixpharma.com/
